Adenylosuccinate lyase enzyme is essential for growth of endocrine therapy resistant ER plus breast cancer cells

被引：0
|
作者：
Yadav, Anil K.
Clarke, Robert
Sengupta, Surojeet
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-391
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
391
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Chromatin remodeling agents enhance efficacy of 17b-estradiol therapy for endocrine-resistant ER plus breast cancer
    Johnson, A.
    Warren, A.
    Traphagen, N.
    Roberts, A.
    Barbara, K.
    Eugene, D.
    Kolling, F.
    Wilkins, O.
    Christensen, B.
    Miller, T.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S86 - S86
  • [22] Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER plus breast cancers
    Dixon, J. Michael
    Turnbull, Arran K.
    Tanioka, Maki
    Wheless, Amy
    Garrett, Amy
    Martinez-Perez, Carlos
    Parker, Joel
    He, Xiaping
    Sims, Andrew H.
    Thomas, Jeremy S.
    Carey, Lisa A.
    Perou, Charles M.
    CANCER RESEARCH, 2018, 78 (04)
  • [23] Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
    Olukoya, Ayodeji O.
    Stires, Hillary
    Bahnassy, Shaymaa
    Persaud, Sonali
    Guerra, Yanira
    Ranjit, Suman
    Ma, Shihong
    Cruz, M. Idalia
    Benitez, Carlos
    Rozeboom, Aaron M.
    Ceuleers, Hannah
    Berry, Deborah L.
    Jacobsen, Britta M.
    Raj, Ganesh V.
    Riggins, Rebecca B.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (10)
  • [24] ARID1A promotes endocrine resistance in ER plus breast cancer cells.
    Chabot, Catherine
    Basik, Mark
    CANCER RESEARCH, 2013, 73 (08)
  • [25] Ribociclib plus Endocrine Therapy in Early Breast Cancer
    Tu, Hengjia
    Zhang, Yuzhuo
    You, Zhixuan
    Li, Qian
    Cai, Yuanxuan
    Li, Jie
    Tannock, Ian F.
    Meirson, Tomer
    Fojo, Antonio
    Slamon, Dennis
    Yardley, Denise A.
    Hortobagyi, Gabriel
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (23): : 2219 - 2222
  • [26] Ribociclib plus Endocrine Therapy in Early Breast Cancer
    Slamon, Dennis
    Lipatov, Oleg
    Nowecki, Zbigniew
    McAndrew, Nicholas
    Kukielka-Budny, Bozena
    Stroyakovskiy, Daniil
    Yardley, Denise A.
    Huang, Chiun-Sheng
    Fasching, Peter A.
    Crown, John
    Bardia, Aditya
    Chia, Stephen
    Im, Seock-Ah
    Ruiz-Borrego, Manuel
    Loi, Sherene
    Xu, Binghe
    Hurvitz, Sara
    Barrios, Carlos
    Untch, Michael
    Moroose, Rebecca
    Visco, Frances
    Afenjar, Karen
    Fresco, Rodrigo
    Severin, Irene
    Ji, Yan
    Ghaznawi, Farhat
    Li, Zheng
    Zarate, Juan P.
    Chakravartty, Arunava
    Taran, Tetiana
    Hortobagyi, Gabriel
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (12): : 1080 - 1091
  • [27] Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC).
    Gumusay, Ozge
    Majure, Melanie Catherine
    Deal, Travis
    Renslo, Jonathan R.
    Wabl, Chiara A.
    Melisko, Michelle E.
    Chien, Amy Jo
    Goga, Andrei
    Moasser, Mark
    Park, John
    Hwang, Jimmy
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] ESR1 gene fusions implicated in endocrine therapy resistance of ER plus breast cancer
    Shao, Jieya
    Zhang, Jin
    Crowder, Robert J.
    Goncalves, Rodrigo
    Phommaly, Chanpheng
    Perou, Charles M.
    Maher, Christopher A.
    Thompson, E. Aubrey
    Ellis, Matthew J.
    CANCER RESEARCH, 2015, 75
  • [29] Mutation signature of patients with ER plus metastatic breast cancer who received endocrine therapy.
    Ma, Fei
    Zhang, Yan
    Ouyang, Quchang
    Dai, Pingping
    Yi, Zongbi
    Cao, Weiguo
    Zhou, Yidong
    Zhu, Chenchen
    Guan, Yan-Fang
    Yang, Ling
    Yi, Xin
    Xia, Xuefeng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Semaphorin 7a promotes cell survival and resistance to endocrine therapy in ER plus breast cancer
    Lyons, Traci Renae
    CANCER RESEARCH, 2020, 80 (16)
12345